151 related articles for article (PubMed ID: 24570340)
61. Anaphylactoid reaction to imiglucerase, but not to alglucerase, in a type I Gaucher patient.
Aviner S; Levy Y; Yaniv I; Cohen IJ
Blood Cells Mol Dis; 1999 Apr; 25(2):92-4. PubMed ID: 10389590
[TBL] [Abstract][Full Text] [Related]
62. Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease.
Zimran A; Wajnrajch M; Hernandez B; Pastores GM
Orphanet J Rare Dis; 2018 Feb; 13(1):36. PubMed ID: 29471850
[TBL] [Abstract][Full Text] [Related]
63. Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease.
Weinreb N; Barranger J; Packman S; Prakash-Cheng A; Rosenbloom B; Sims K; Angell J; Skrinar A; Pastores GM
Clin Genet; 2007 Jun; 71(6):576-88. PubMed ID: 17539908
[TBL] [Abstract][Full Text] [Related]
64. Cognitive outcome in treated patients with chronic neuronopathic Gaucher disease.
Goker-Alpan O; Wiggs EA; Eblan MJ; Benko W; Ziegler SG; Sidransky E; Schiffmann R
J Pediatr; 2008 Jul; 153(1):89-94. PubMed ID: 18571543
[TBL] [Abstract][Full Text] [Related]
65. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase.
Zimran A; Pastores GM; Tylki-Szymanska A; Hughes DA; Elstein D; Mardach R; Eng C; Smith L; Heisel-Kurth M; Charrow J; Harmatz P; Fernhoff P; Rhead W; Longo N; Giraldo P; Ruiz JA; Zahrieh D; Crombez E; Grabowski GA
Am J Hematol; 2013 Mar; 88(3):172-8. PubMed ID: 23339116
[TBL] [Abstract][Full Text] [Related]
66. Treatment patterns from 647 patients with Gaucher disease: An analysis from the Gaucher Outcome Survey.
Deegan P; Fernandez-Sasso D; Giraldo P; Lau H; Panahloo Z; Zimran A
Blood Cells Mol Dis; 2018 Feb; 68():218-225. PubMed ID: 27829541
[TBL] [Abstract][Full Text] [Related]
67. Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology.
Grabowski GA; Golembo M; Shaaltiel Y
Mol Genet Metab; 2014 May; 112(1):1-8. PubMed ID: 24630271
[TBL] [Abstract][Full Text] [Related]
68. Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series.
Serratrice C; Swiader L; Serratrice J
J Med Case Rep; 2015 Jun; 9():146. PubMed ID: 26100396
[TBL] [Abstract][Full Text] [Related]
69. Bone marrow involvement in Gaucher disease at MRI : what long-term evolution can we expect under enzyme replacement therapy?
Fedida B; Touraine S; Stirnemann J; Belmatoug N; Laredo JD; Petrover D
Eur Radiol; 2015 Oct; 25(10):2969-75. PubMed ID: 25875285
[TBL] [Abstract][Full Text] [Related]
70. Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early Access Program results from Jerusalem.
Elstein D; Altarescu G; Maayan H; Phillips M; Abrahamov A; Hadas-Halpern I; Tiomkin M; Zimran A
Blood Cells Mol Dis; 2012 Jan; 48(1):45-50. PubMed ID: 22047948
[TBL] [Abstract][Full Text] [Related]
71. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
Pastores GM
Curr Opin Investig Drugs; 2010 Apr; 11(4):472-8. PubMed ID: 20336596
[TBL] [Abstract][Full Text] [Related]
72. RPEM: Randomized Monte Carlo parametric expectation maximization algorithm.
Chen R; Schumitzky A; Kryshchenko A; Nieforth K; Tomashevskiy M; Hu S; Garreau R; Otalvaro J; Yamada W; Neely MN
CPT Pharmacometrics Syst Pharmacol; 2024 May; 13(5):759-780. PubMed ID: 38622792
[TBL] [Abstract][Full Text] [Related]
73. Evolving features in type 3 Gaucher disease on long-term enzyme replacement therapy.
Elstein D; Abrahamov A; Altarescu G; Zimran A
Blood Cells Mol Dis; 2013 Feb; 50(2):140. PubMed ID: 23085428
[No Abstract] [Full Text] [Related]
74. Dynamic changes of lipid profile in Romanian patients with Gaucher disease type 1 under enzyme replacement therapy: a prospective study.
Zimmermann A; Grigorescu-Sido P; Rossmann H; Lackner KJ; Drugan C; Al Khzouz C; Bucerzan S; Naşcu I; Zimmermann T; Leucuţa D; Weber MM
J Inherit Metab Dis; 2013 May; 36(3):555-63. PubMed ID: 22976766
[TBL] [Abstract][Full Text] [Related]
75. Enzyme replacement therapy "drug holiday": results from an unexpected shortage of an orphan drug supply in Australia.
Goldblatt J; Fletcher JM; McGill J; Szer J; Wilson M
Blood Cells Mol Dis; 2011 Jan; 46(1):107-10. PubMed ID: 20684886
[TBL] [Abstract][Full Text] [Related]
76. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement.
Elstein D; Dweck A; Attias D; Hadas-Halpern I; Zevin S; Altarescu G; Aerts JF; van Weely S; Zimran A
Blood; 2007 Oct; 110(7):2296-301. PubMed ID: 17609429
[TBL] [Abstract][Full Text] [Related]
77. Immunoglobulin abnormalities and effects of enzyme replacement therapy in children with Gaucher disease.
Arıkan-Ayyıldız Z; Yuce A; Uslu-Kızılkan N; Demir H; Gurakan F
Pediatr Blood Cancer; 2011 Apr; 56(4):664-6. PubMed ID: 21298757
[TBL] [Abstract][Full Text] [Related]
78. Effects of switching from imiglucerase to velaglucerase alfa without dose reduction nor wash out in type 1 Gaucher disease.
Serratrice C; Bengherbia M; Alessandrini M; Grosbois B; Camou F; Pers YM; Bismuth M; Marie I; Belmatoug N; Berger M;
Blood Cells Mol Dis; 2014; 53(1-2):94-6. PubMed ID: 24411065
[No Abstract] [Full Text] [Related]
79. Improvement In Symptoms Of Gaucher's Disease By Enzyme Replacement Therapy.
Mazher W; Ali J; Abubakar S; Basar S; Murtaza G
J Ayub Med Coll Abbottabad; 2018; 30(3):479-481. PubMed ID: 30465391
[TBL] [Abstract][Full Text] [Related]
80. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.
Charrow J; Dulisse B; Grabowski GA; Weinreb NJ
Clin Genet; 2007 Mar; 71(3):205-11. PubMed ID: 17309642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]